VIFOR-PHARMA
14.12.2021 06:46:07 CET | Business Wire | Press release
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies, today announced that they have entered into a definitive agreement for CSL to acquire Vifor Pharma for an aggregate equity value for Vifor Pharma of US$ 11.7 / CHF 10.9 billion.
CSL has offered to acquire Vifor Pharma in an all-cash tender offer of US$179.25 (CHF 167) per share, payable in U.S. dollars.1 The offer assumes a dividend of CHF 2 expected to be declared at the AGM of 26 April, consistent with past practice.
The tender offer represents an implied premium of approximately 61% to the unaffected closing price of Vifor Pharma on 1 December 2021 and a 47% premium to Vifor Pharma’s unaffected 1-month VWAP as of 1 December 2021.2
Patinex AG, Vifor Pharma’s largest shareholder holding 23.2% has agreed to tender its shares into the offer.
The Transaction remains subject to the conditions and further terms including:
- Minimum acceptance rate of 80% of all Vifor Pharma shares on a fully diluted basis; and
- further customary offer conditions, including regulatory approvals.
The tender is currently expected to commence around 18 January 2022 and the transaction is expected to complete around mid-2022.
The Board of Directors of Vifor Pharma considers that the proposed transaction respects the interests of all stakeholders and is unanimously recommending the offer to shareholders. There is committed financing for the deal and a strong commitment to pursue regulatory clearances.
“Vifor Pharma's strategy has been to focus towards continuing being a market leader in iron deficiency, nephrology and cardio-renal therapies.” Jacques Theurillat, Chairman of the Board of Directors Vifor Pharma Group commented. “The offer provides an excellent strategic opportunity for Vifor Pharma to optimize future market opportunities from a position of strength and to create substantial value for all stakeholders.”
The transaction will enable Vifor Pharma to leverage CSL’s global reach, balance sheet and capabilities to bring more products to patients within its key categories. The transaction also enables Vifor Pharma to accelerate growth in cardiovascular-metabolic, renal and transplant.
Centerview Partners UK LLP is acting as exclusive financial advisor to Vifor Pharma on the transaction.
IFBC have been retained as Fairness Opinion providers by the Vifor Pharma Board of Directors.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com .
About CSL
CSL (ASX: CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus- provides life-saving products to more than 100 countries and employs more than 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information visit csl.com.
Legal Disclaimers
Important Additional Information
The tender offer described herein has not yet commenced. This release is for informational purposes only and does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any registered shares or other equity securities in Vifor Pharma Ltd., nor shall it form the basis of, or be relied on in connection with, any contract therefor. This release is not part of the offer documentation relating to the tender offer. Main terms and conditions of the tender offer have been published in today's Pre-Announcement of the tender offer, and full details including terms and conditions will be published in the tender offer prospectus. Shareholders of Vifor Pharma Ltd. are urged to read the tender offer documents, which are or will be available at www.CSLtransaction.com .
Certain Offer Restrictions
Reference is made to the Pre-Announcement of the tender offer published today for full offer restrictions.
1 At USD to CHF FX rate of 0.932.
2 Based on the last closing price of Vifor Pharma prior to public speculation regarding a potential transaction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213006121/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yamaha Motor to Exhibit All-New RW Series’ RW700 and RW350 at EICMA4.11.2026 10:00:00 CET | Press release
- Adventure Scooters Bringing New Enjoyment to Mobility - Yamaha Motor Co., Ltd. (TOKYO: 7272) announced today that it will exhibit its new RW700 and RW350 models at EICMA 2026 (International Two-Wheeler Exhibition), one of Europe's largest motorcycle shows, to be held in Milan, Italy, from November 3rd. “RW” is an all-new series of models for global markets developed as new adventure scooters to transform everyday mobility into an experience bringing more color to people's lifestyles. The RW Series aims to offer new mobility experiences that seamlessly connect everyday life with the extraordinary, opening up new possibilities and discoveries in people’s lives by letting them explore detours off familiar roads that lead them to new sights and Kando. In addition to providing comfort and ease of use for urban environments, the RW Series boasts features and performance that entice users to freely turn off familiar roads and head out toward new scenery and experiences. The styling features
ANS Cuts IT Alert Noise by 83% with LogicMonitor Edwin AI4.11.2026 09:30:00 CET | Press release
Early results also show 45% fewer observability cases and 44% faster incident resolution, giving ANS engineers more time to improve customer services LogicMonitor®, the AI-first platform for Autonomous IT, and ANS Group, a leading UK technology and managed services provider, today announced early results from ANS's deployment of Edwin AI, demonstrating how AI is helping reshape managed services by reducing routine operational work and creating more capacity for proactive customer value. Since deploying Edwin AI in August 2026, ANS has reduced alert noise by 83%, observability incident volumes by 45% and average incident resolution times by 44%, while reporting a 500% return on its incremental Edwin AI investment.* ANS has also consistently maintained SLA performance above 97%. By correlating related alerts, accelerating investigations and recommending next steps, Edwin AI is helping ANS shift engineering capacity from reactive incident management toward more proactive customer services
LogicMonitor Makes AI the Standard, Not the Upgrade4.11.2026 09:00:00 CET | Press release
New platform packages include Edwin AI and Digital Experience at every tier, uniting signals, context and governed action on one licensing model LogicMonitor®, the AI-first platform for Autonomous IT, today announced new platform packages that make Edwin AI and LogicMonitor Digital Experience, including Synthetics and Internet Sonar, standard in every tier. By bringing full digital experience and internet health visibility together with AI-driven operations in every package, LogicMonitor helps teams connect what users experience to the signals behind it and move toward a governed next step. AI is now essential to modern IT operations, yet too often, the capabilities needed to put it into practice remain fragmented across tools and licensing models. As enterprises move toward Autonomous IT, access to AI-driven intelligence and end-to-end visibility must become the foundation, not an added layer of complexity. “IT teams don't need more separate Observability tools with AI bolted on; they
AiDEN Auto and Volvo Trucks First to Offer Embedded E-Transportation Regulatory Compliance Through the Infotainment System4.11.2026 09:00:00 CET | Press release
An industry-first integration brings RO e-Trans compliance monitoring directly into the Volvo Trucks infotainment interface and Volvo Connect, making regulatory management easier, safer, and more efficient for drivers and fleets. AiDEN Auto, a pioneer in connected vehicle software solutions, has partnered with Volvo Trucks to integrate RO e-Trans regulatory compliance management directly into the truck's in-cab infotainment system and the Volvo Connect back-office portal. Made available through Volvo Trucks' suite of digital services and Volvo Connect ecosystem, this innovative application allows drivers and fleet managers to monitor and maintain compliance with Romania's mandatory national e-Transport regulations in real time—without leaving the cab or relying on secondary mobile devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104342472/en/ AiDEN Auto, a pioneer in connected vehicle software solutions, has partne
Azerbaijan Signs its Participation Contract in Expo 2030 Riyadh4.11.2026 08:47:00 CET | Press release
The Republic of Azerbaijan has signed its Participation Contract in Expo 2030 Riyadh. The contract was signed by Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh and H.E. Mr. Anar Alakbarov, Assistant to the President of the Republic of Azerbaijan, during a ceremony held in Baku, Azerbaijan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103050461/en/ The contract was signed by Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh and H.E. Mr. Anar Alakbarov, Assistant to the President of the Republic of Azerbaijan, during a ceremony held in Baku, Azerbaijan. The signing marks an important milestone in Azerbaijan’s participation journey, allowing it to move from planning into delivery of its presence at Expo 2030 Riyadh. Holding the ceremony in Baku reflects the longstanding friendship between the Republic of Azerbaijan and the Kingdom of Saudi Arabia, as well as the importance Azerbaijan attaches to its
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom